NCT06242652View on ClinicalTrials.gov

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

June 15, 2025

Conditions
Ankylosing Spondylitis
Interventions
DRUG

608 Dose A

608 subcutaneous (SC) injection.

DRUG

608 Dose B

608 subcutaneous (SC) injection.

DRUG

608 Dose C

608 subcutaneous (SC) injection.

DRUG

Adalimumab

Adalimumab subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (1)

100730

Site 01, Beijing

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY